Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Open accessThe DOI matches its Crossref record; 28 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. However, this combined approach provides correct therapeutic and prognostic information in only 50 percent of cases. METHODS: We determined the gene-expression profiles in samples of peripheral blood or bone marrow from 285 patients with AML using Affymetrix U133A GeneChips containing approximately 13,000 unique genes or expression-signature tags. Data analyses were carried out with Omniviz, significance analysis of microarrays, and prediction analysis of microarrays software. Statistical analyses were performed to determine the prognostic significance of cases of AML with specific molecular signatures. RESULTS: Unsupervised cluster analyses identified 16 groups of patients with AML on the basis of molecular signatures. We identified the genes that defined these clusters and determined the minimal numbers of genes needed to identify prognostically important clusters with a high degree of accuracy. The clustering was driven by the presence of chromosomal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations (CEBPA), and abnormal oncogene expression (EVI1). We identified several novel clusters, some consisting of specimens with normal karyotypes. A unique cluster with a distinctive gene-expression signature included cases of AML with a poor treatment outcome. CONCLUSIONS: Gene-expression profiling allows a comprehensive classification of AML that includes previously identified genetically defined subgroups and a novel cluster with an adverse prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These observations were extended and recapitulated in analyses of public gene expression data (figure S5)(35–40).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Diagnosis of multiple cancer types by shrunken centroids of gene expression
Tibshirani, R., Hastie, T., Narasimhan, B., & Chu, G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082099299 · Cited by 2,930
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723 · cited 2×
“(%) <35 yr 35–60 yr ≥60 yr 76 (27) 177 (62) 32 (11)”
BackgroundSlovak, M. L., Kopecky, K. J., Cassileth, P. A., Harrington, D. H., Theil, K. S., Mohamed, A., Paietta, E., Willman, C. L., Head, D. R., Rowe, J. M., et al. (2000) · Blood · doi:10.1182/blood.v96.13.4075 · Cited by 1,601
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558 · cited 2×
“(%)* t(15;17) t(8;21) inv(16)/t(16;16) +8 +11 +21 ¡5 ¡5(q) ¡7 ¡7(q) 3q t(6;9) t(9;22) t(11q23) Complex karyotype (>3 chromosomal abnormalities) Other abnormal karyotypes Normal karyotype Not determined 18 (6) 22 (8) 19 (7) 26 (9) 7 (2) 2 (1) 3 (1) 1 (<1) 13 (5) 7 (2) 6 (2) 4 (1) 2 (1) 19 (7) 11 (4) 60 (21) 119 (42) 10…”
Research works printed but not linked: 1
- 17. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. Blood (in press).
Cited by
Items 901–1,000 of 1,000
New approaches in acute myeloid leukemia
Blum, W. G., & Marcucci, G. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.11.009 · Cited by 10
The Use of Molecular Genetics to Refine Prognosis in Acute Myeloid Leukemia
Bhatnagar, B., & Garzon, R. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0208-3 · Cited by 13
The clinical importance of CD4 + CD7 − in human diseases
Haftcheshmeh, S. M., Tajbakhsh, A., Kazemi, M., Esmaeili, S., Mardani, F., Fazeli, M., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27099 · Cited by 10
“Evidence suggests that increase in expression of the CD7 antigen on the leukemic cells of patients with acute myeloid leukemia (AML) is due to several mutations in CEBPA (Lin et al., 2005; Valk et al., 2004).”
BackgroundInfluentialUmeki, S., Tamai, H., Yagi, S., Soejima, R., & Higashi, Y. (1990) · Rinsho Shinkeigaku · Cited by 10
Fuchs, O., Kostečka, A., Provazníková, D., Krasna, B., Kotlín, R., Staňková, M., Kobylka, P., Dostálová, G., Zeman, M., & Chochola, M. (2010) · Folia Biologica · doi:10.14712/fb2010056020051 · Cited by 10
Expression genomics and drug development: Towards predictive pharmacology
Liu, E. T. (2005) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/3.4.303 · Cited by 11
“Valk et al.66 uncovered expression-defined gene clusters associated with specific cytogenetic abnormalities that could predict cytogenetic configuration in a separate validation set.”
BackgroundClofarabine for the Treatment of Adult Acute Myeloid Leukemia
Thomas, X., Raffoux, E., Elhamri, M., Lobe, I., Cannas, G., & Dombret, H. (2009) · Future Oncology · doi:10.2217/fon.09.105 · Cited by 10
Acute myeloid leukemia in adults
Burnett, A. K. (2004) · CRC Press eBooks · doi:10.1201/b14440-39 · Cited by 10
Onciu, M. M., & Pui, C. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511977633.003 · Cited by 10
Towards a pathogenesis-oriented therapy of acute myeloid leukemia
Hiddemann, W., Spiekermann, K., Buske, C., Feuring‐Buske, M., Braess, J., Haferlach, T., Schoch, C., Kern, W., Schnittger, S., Berdel, W. E., et al. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.07.004 · Cited by 10
Clinical utility of serum biomarkers for major psychiatric disorders
van Beveren, N. J. M., & Hoogendijk, W. J. G. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-387718-5.00014-6 · Cited by 11
Hegde, M. B., Ahmad, M. H., Mulet‐Lazaro, R., Sugita, M., Li, R., Hu, K., Gebhard, C., Guzmán, M. L., Bushweller, J. H., Zhu, L. J., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02471-9 · Cited by 10
“In acute myeloid leukemia (AML), founding mutations in genes encoding transcription factors can subvert regulatory networks in the hematopoietic stem and progenitor cells (HSPCs) and drive leukemogenesis with speci fi c transcription and epigenetic signatures [4, 5].”
Self-citationMolecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML
Rücker, F. G., Bullinger, L., Gribov, A., Sill, M., Schlenk, R. F., Lichter, P., Döhner, H., & Döhner, K. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20830 · Cited by 9
“High-resolution profiling of submicroscopic genomic aberrations using arrayCGH or single nucleotide polymorphism (SNP) arrays has already provided new insights in AML, not only in cases with known abnormal karyotype (Walter et al., 2009), but also in CN-AML.”
BackgroundThe Future of Diagnostic Gene-Expression Microarrays: Bridging The Gap Between Bench and Bedside
Roepman, P. (2010) · Bioanalysis · doi:10.4155/bio.09.172 · Cited by 9
The modular network structure of the mutational landscape of Acute Myeloid Leukemia
Ibáñez, M., Carbonell‐Caballero, J., Such, E., García‐Alonso, L., Liquori, A., López‐Pavía, M., Llop, M., Alonso, C., Barragán, E., Gómez‐Seguí, I., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202926 · Cited by 9
Zhong, P., Liu, L., Shen, A., Chen, Z., Hu, X., Cai, Y., Lin, J., Wang, B., Li, J., Chen, Y., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10982 · Cited by 9
“Thanks to the rapid development and extensive application of microarrays for gene identification in various types of cancer (20-22), a high number of differentially expressed genes (DEGs) in OTSCC have been identified (13,19).”
BackgroundHOXA11 plays critical roles in disease progression and response to cytarabine in AML
Fu, J., Shih, L., & Yen, T. (2021) · Oncology Reports · doi:10.3892/or.2021.8101 · Cited by 9
A novel necroptosis-related gene signature in acute myeloid leukemia
Fang, W., Lin, H., Chen, J., & Guo, W. (2023) · Hematology · doi:10.1080/16078454.2023.2227491 · Cited by 9
“The prognosis of AML is highly heterogeneous due to the molecular di ff erences between patients [1].”
BackgroundChen, J., Huang, C., Zhu, Y., Dong, L., Cao, W., Sun, L., Sun, H., Wan, D., Liu, Y., Zhang, Z., et al. (2015) · Pathology - Research and Practice · doi:10.1016/j.prp.2015.07.007 · Cited by 9
Kennedy, L., Vass, J. K., Haggart, D. R., Moore, S. C., Burczynski, M. E., Crowther, D., & Miele, G. (2008) · Biomarker Insights · doi:10.4137/bmi.s938 · Cited by 9
“…profi les have been well established (Alizadeh et al. 2000; Baechler et al. 2003; Bullinger et al. 2004; Crow and Wohlgemuth, 2003; Golub et al. 1999; Han et al. 2003; Maas et al. 2002; McLean et al. 2004; Moos et al. 2002; Nowicki et al. 2003; Valk et al. 2004; Bennett et al. 2003).”
Hassan, S., & Smith, M. (2014) · Hematology · doi:10.1179/1024533214z.000000000312 · Cited by 10
Genomic approaches in acute leukemia
Stegmaier, K. (2006) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.11.001 · Cited by 9
Jo, A., Tsukimoto, I., Ishii, E., Asou, N., Mitani, S., Shimada, A., Igarashi, T., Hayashi, Y., & Ichikawa, H. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07531.x · Cited by 11
“…which have been repeatedly identified as overexpressed genes in MLLgr(+) leukaemia (Armstrong et al, 2002; Yeoh et al, 2002; Tsutsumi et al, 2003; Bullinger et al, 2004; Ross et al, 2004; Valk et al, 2004; Andersson et al, 2005; Kohlmann et al, 2005), were not included in the selected gene lists.”
BackgroundInfluentialKern, W., Kohlmann, A., Schoch, C., Schnittger, S., & Haferlach, T. (2006) · Cancer · doi:10.1002/cncr.22251 · Cited by 9
Suspected leukemia oncoproteins CREB1 and LYL1 regulate Op18/STMN1 expression
San‐Marina, S., Han, Y., Liu, J., & Minden, M. D. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2012.09.004 · Cited by 9
PPARδ is a ligand-dependent negative regulator of vitamin D3-induced monocyte differentiation
Lymboussaki, A., Gemelli, C., Testa, A., Facchini, G., Ferrari, F., Mavilio, F., & Grande, A. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn272 · Cited by 9
A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC
Brand, J., van Vliet, M. H., de Best, L., Valk, P. J. M., Viëtor, H. E., Löwenberg, B., & van Beers, E. H. (2013) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-2-7 · Cited by 9
“218 Measurements of BAALC, EVI1, ERG and MN1 expression Training and validation expression levels are measured in RNA extracted from ficoll purified blast cells from diagnostic BM and PB samples as previously described [22].”
MethodSelf-citationPerspectives of gene expression profiling for diagnosis and therapy in haematological malignancies
Bacher, U., Kohlmann, A., & Haferlach, T. (2009) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/elp011 · Cited by 9
“One main focus was the reproduction of known subentities based on specific gene expression patterns (‘class prediction’) [13, 15–17].”
BackgroundGenes and pathways associated with the occurrence of malignancy in benign lymphoepithelial lesions
Adzavon, Y. M., Zhao, P., Zhang, X., Liu, M., Lv, B., Yang, L., Zhang, X., Xie, F., Zhang, M., Ma, J., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8149 · Cited by 9
“It was used for class discovery and prediction, or for prediction of molecular markers, and for evaluation of the response to therapeutic compounds (14-19).”
Pieters, T., T’Sas, S., Demoen, L., Almeida, A., Haenebalcke, L., Matthijssens, F., Lemeire, K., D’Hont, J., Rockeghem, F. V., Hochepied, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46853-x · Cited by 9
Transcriptomics: Translation of Global Expression Analysis to Genomic Medicine
Kittleson, M. M., Irizarry, R. A., Heidecker, B., & Hare, J. M. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-369420-1.00012-3 · Cited by 9
Han, H., Shin, D., Kim, D., Kim, H., Lee, C., Koh, Y., Hong, J., & Yoon, S. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1747062 · Cited by 10
Molecular biology in acute leukemia
Camós, M., & Colomer, D. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0060-6 · Cited by 9
Modern genome-wide genetic approaches to reveal intrinsic properties of stem cells
de Haan, G., Gerrits, A., & Bystrykh, L. V. (2006) · Current Opinion in Hematology · doi:10.1097/01.moh.0000231422.00407.be · Cited by 9
Has gene expression profiling improved diagnosis, classification, and outcome prediction in AML?
Willman, C. L. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.11.008 · Cited by 9
Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children
Clark, J., Berman, J. N., & Look, A. T. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3431-5.00011-x · Cited by 10
Microarrays and Crohn's disease: Collecting reliable information
Csillag, C., Nielsen, O. H., Borup, R., & Nielsen, F. C. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510012226 · Cited by 9
“Efforts aimed at discovery of previously unrecognized disease subgroups based on differential gene expression profiles have already produced results for multiple myeloma [4] and lymphoma [5], and in various studies it has been possible to assign a particular gene expression profile to known clinically relevant disease…”
BackgroundDombret, H., & Gardin, C. (2009) · New England Journal of Medicine · doi:10.1056/nejme0905678 · Cited by 9
Almaghrabi, R. O. M., Alyahyawi, Y., Keane, P., Mian, S. A., Habel, K., Atkinson, A., Ward, C., Bayley, R., Sargas, C., Menéndez, P. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60192-8 · Cited by 10
“By performing GSEA with available gene signatures from HSC 46,47 , LSC 46,48 , and AML harbouring a CEBPA mutation 49 , we observed an HSC, and possibly LSC-like signature in MDS clusters 6 and 7, with sets of genes that have been found to be downregulated in…”
Schnittger, S., Bacher, U., Eder, C., Lohse, P., Haferlach, C., Kern, W., & Haferlach, T. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.09.009 · Cited by 8
Saifullah, S., & Tsukahara, T. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09878 · Cited by 8
“This observation is consistent with those of previous studies [31, 32, 33].”
ResultSTING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells
Sun, Y., Wu, Y., Pang, G.-Z., Huang, J., Sheng, M., Xie, J., Chen, P., Wang, Y., Yin, D., Zhao, G., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02383-8 · Cited by 9
“Among various genetic alterations identi fi ed in AML, the t(8;21) translocation is relatively frequent, found in approximately 5 to 10% of all AML cases [3 – 5].”
Decoding Acute Myeloid Leukemia: A Clinician’s Guide to Functional Profiling
Iyer, P., Jasdanwala, S. S., Wang, Y., Bhatia, K. S., & Bhatt, S. (2024) · Diagnostics · doi:10.3390/diagnostics14222560 · Cited by 8
Fos, J., Pabst, T., Petkovic, V., Ratschiller, D., & Mueller, B. U. (2011) · Blood · doi:10.1182/blood-2010-11-320747 · Cited by 11
Wurm, M., Kowalski, J. P., Heckl, D., Zhang, X.-B., Nelson, V., Beard, B. C., & Kiem, H. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.10.004 · Cited by 10
“Gene expression analysis of the HOXC6-overexpressing aberrant myeloid progenitors thus showed induction of a stemness phenotype and AML-like traits [18-20] that were accompanied by signatures of myeloid transcription factors (Supplemental Figure 2B).”
BackgroundFunction of Deptor and its roles in hematological malignancies
Morales-Martínez, M., Lichtenstein, A. K., & Vega, M. I. (2021) · Aging · doi:10.18632/aging.202462 · Cited by 8
Schittenhelm, M. M., Kaiser, M., Győrffy, B., & Kampa-Schittenhelm, K. M. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06372-0 · Cited by 8
“Cells were cultured in RPMI 1640, supplemented with 10% fetal bovine serum, 1% penicillin G (10 000 units/mL) and streptomycin (10,000µg/mg) and 2 mmol/L l-glutamine (GIBCO/Invitrogen, Darmstadt, Germany or Biochrom AG, Berlin, Germany).”
MethodGene function classification using NCI-60 cell line gene expression profiles
Ko, D., Xu, W., & Windle, B. E. (2005) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2005.09.003 · Cited by 8
CARD15 Status and Familial Predisposition for Crohn's Disease and Colonic Gene Expression
Csillag, C., Nielsen, O. H., Borup, R., Olsen, J., Bjerrum, J. T., & Nielsen, F. C. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9737-5 · Cited by 8
“One of the best-studied diseases with DNA microarrays is acute myeloid leukemia (AML), in which not only known AML classes could be predicted, but new subtypes of the disease have been proposed [47, 48].”
BackgroundAhmad, F., Rajput, S., Mandava, S., & Das, B. R. (2012) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2011.0317 · Cited by 8
“Most reports of CEBPA mutations come from Western countries (Pabst et al ., 2001; Valk et al ., 2004; Green et al ., 2010; Szankasi et al ., 2011), while there are a few reports from Asia (Leecharendkeat et al ., 2008; Ahn et al ., 2009; Mizushima et al ., 2010; Shen et al ., 2011).”
Haladyna, J. N., Pastuer, T., Riedel, S. S., Perraud, A., & Bernt, K. M. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.03.006 · Cited by 8
“Given reports that knockdown or inhibition of TRPM2 enhanced killing by cytotoxic agents in neuroblastoma, breast and prostate cancer cell lines (8, 19, 20), we next exposed Trpm2wt and Trpm2−/− MLL-AF9 leukemias to doxorubicin, cytarabine, and etoposide in vitro.”
BackgroundMicroRNA-155 induces AML in combination with the loss of C/EBPA in mice
Alemdehy, M. F., de Looper, H. W. J., Kavelaars, F. G., Sanders, M. A., Hoogenboezem, R. M., Löwenberg, B., Valk, P. J. M., Touw, I. P., & Erkeland, S. J. (2016) · Leukemia · doi:10.1038/leu.2016.171 · Cited by 8
Self-citationTwo effects of GATA2 enhancer repositioning by 3q chromosomal rearrangements
Suzuki, M., Katayama, S., & Yamamoto, M. P. (2019) · IUBMB Life · doi:10.1002/iub.2191 · Cited by 8
Boujmia, O. K. A., Lamchahab, M., Hda, N., & Quessar, A. (2021) · Asian Pacific Journal of Cancer Biology · doi:10.31557/apjcb.2021.6.1.5-13 · Cited by 8
“6% for the adverse group respectively similar results were reported by other authors [48-67, 68].”
BackgroundResultShang, L., Cai, X., Sun, W., Cheng, Q.-N., & Mi, Y. (2021) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.22028 · Cited by 8
“The t(8;21) abnormality is found in 5%–10% of all AML cases and 10%–22% of AML cases with maturation corresponding to the previous FAB M2 (Arber et al., 2003; Cheng et al., 2009; Grimwade et al., 2010; Klaus et al., 2004; Sanderson et al., 2006; Valk et al., 2004).”
ResultJeanty, C., Longrois, D., Mertès, P., Wagner, D. R., & Devaux, Y. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-542 · Cited by 8
“Consistently, while biosignatures of blood cells were originally reported to be a useful prognostic tool for acute myeloid leukemia [1,2], several studies later showed that these biosignatures can also aid in the development of biomarkers of several diseases affecting vital organs such as the brain [3] and the coronar…”
BackgrounddCaP: detecting differential binding events in multiple conditions and proteins
Chen, K.-B., Hardison, R. C., & Zhang, Y. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-s9-s12 · Cited by 8
“The MSigDB Perturbation ontology also showed enrichment of the top 40 genes from cluster 7 of acute myeloid leukemia (AML) expression profile in a previous study [47].”
A platform for the selection of genes in DNA microarraydata using evolutionary algorithms
Rocha, M., Mendes, R., Maia, P., Glez‐Peña, D., & Fdez‐Riverola, F. (2007) · Genetic and Evolutionary Computation Conference (GECCO) · doi:10.1145/1276958.1277042 · Cited by 8
“and variable responses to treatment [16].”
Yeoh, A. E. J., Li, Z., Dong, D., Lü, Y., Jiang, N., Trka, J., Tan, A. M., Lin, H. P., Quah, T. C., Ariffin, H., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15252 · Cited by 8
“…profiling (GEP) can subtype various haematological malignancies like ALL (Yeoh et al, 2002; Haferlach et al, 2010), acute myeloid leukaemia (Schoch et al, 2002; Valk et al, 2004; Balgobind et al, 2011) and lymphoma (Alizadeh et al, 2000) subgroups with an exceedingly high accuracy of >95%.”
BackgroundTranscriptional Profiling of Hematologic Malignancies with a Low-Density DNA Microarray
Álvarez, P., Sáenz, P., Arteta, D., Martínez, A., Pocovı́, M., Simón, L., & Giraldo, P. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.075887 · Cited by 8
“In addition, other studies that have applied this technology have identified HN disease subgroups not previously known to be related (3, 4) and discovered new prognostic markers for such diseases (5 ).”
Ginsburg, G. S., & Angrist, M. H. (2006) · Personalized Medicine · doi:10.2217/17410541.3.2.119 · Cited by 8
“But when, for example, gene expression signatures with predictive value are recognized for their potential clinical utility in diffuse large B-cell lymphomas [2], acute myeloid leukemias [3,4], breast cancer [5–9], and even cardiovascular disease [10], the future may be closer than we think.”
BackgroundOyan, A. M., Bø, T. H., Jonassen, I., Gjertsen, B. T., Bruserud, Ø., & Kalland, K. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.5.1065 · Cited by 8
Cytogenetically Normal Acute Myeloid Leukemia
Büchner, T., Berdel, W. E., & Kienast, J. (2008) · New England Journal of Medicine · doi:10.1056/nejmc081230 · Cited by 8
Discussion of the Applicability of Microarrays: Profiling of Leukemias
Haferlach, T., Bacher, U., Kohlmann, A., & Haferlach, C. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-372-1_2 · Cited by 8
Large scale analysis of signal reachability
Todor, A., Gabr, H., Dobra, A., & Kahveci, T. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu262 · Cited by 7
“Understanding how gene regulation is affected by such aberrations is of utmost importance.”
BackgroundZhong, J., Huang, K., Xie, S., Tan, A., Peng, J., Nie, D., Ma, L., & Li, Y. (2024) · Journal of Cancer · doi:10.7150/jca.90822 · Cited by 7
“While such potential mutations may contribute to leukemic development and progression, they may be potential therapeutic targets that provide new insights for drug development [3].”
BackgroundMeasures of Association for Identifying MicroRNA-mRNA Pairs of Biological Interest
Jayaswal, V., Lutherborrow, M. A., & Yang, J. Y. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029612 · Cited by 8
“[46–48].”
The Impact of Molecular Genetic in Acute Myeloid Leukemias
P, P. A. S. (2015) · Journal of Blood Disorders & Transfusion · doi:10.4172/2155-9864.1000252 · Cited by 7
Integrative Oncogenomic Analysis of Microarray Data in Hematologic Malignancies
Martinez-Climent, J. A., Fontán, L., Fresquet, V., Robles, E. F., Ortiz, M., & Rubio, Á. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-545-9_13 · Cited by 7
Marneth, A. E., Prange, K. H. M., Hinai, A. S. A. A., Bergevoet, S. M., Tesi, N., Janssen‐Megens, E. M., Kim, B., Sharifi, N., Yaspo, M., Kuster, J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.280 · Cited by 8
Self-citationVillar, S., Ariceta, B., Agirre, X., Urribarri, A. D., Ayala, R. M., Martínez‐Cuadrón, D., Bergua, J., Vives, S., Algarra, L., Tormo, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1054458 · Cited by 7
K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML)
Carnicer, M. J., Lasa, A., Buschbeck, M., Serrano, E., Carricondo, M., Brunet, S., Aventin, A. M., Sierra, J., Croce, L. D., & Nomdedeu, J. F. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0528-2 · Cited by 10
“Expression microarrays [ 42 ], single nucleotide polymorphism microarray mapping assay, and structure prediction of CEBPA mutants were performed as reported elsewhere.”
MethodDetection of CEBPA Double Mutants in Acute Myeloid Leukemia Using a Custom Gene Expression Array
van Vliet, M. H., Burgmer, P., de Quartel, L., Brand, J., de Best, L., Viëtor, H. E., Löwenberg, B., Valk, P. J. M., & van Beers, E. H. (2013) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0437 · Cited by 7
“2Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.”
MethodSelf-citationMolecular characterization of AML: A significant advance or just another prognostic factor?
Schiffer, C. A. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.08.006 · Cited by 7
Genomic testing in myeloid malignancy
Docking, R., & Karsan, A. (2019) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13022 · Cited by 7
Rubnitz, J. E., Razzouk, B. I., & Ribeiro, R. C. (2006) · Cambridge University Press eBooks · doi:10.1017/cbo9780511471001.020 · Cited by 8
Gadd45 in Normal Hematopoiesis and Leukemia
Liebermann, D. A. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-94804-7_3 · Cited by 7
The role of molecular genetic analysis within the diagnostic haemato‐oncology laboratory
Bench, A. J. (2011) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2011.01364.x · Cited by 7
“Gene expression profiling can reliably differentiate subtypes of different leukaemias (Valk et al., 2004; Haferlach et al., 2010) and may be useful for cases that are difficult to classify by traditional methods.”
BackgroundAcute myeloid leukemia: leukemia stem cells write a prognostic signature
Gudgin, E. J., & Huntly, B. J. P. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt62 · Cited by 7
“Global gene expression profi les of bulk leukemia cells have provided further data to improve classifi cation and prognosis [3,4], and have identifi ed overexpression of specifi c genes, such as BAALC and ERG, to be associated with poor survival.”
BackgroundVarn, F. S., Andrews, E. H., & Cheng, C. (2015) · Scientific Reports · doi:10.1038/srep16987 · Cited by 8
Zhao, X.-Y., Zhang, R., Ye, Q., Qiu, F., Xu, H., Wei, F.-G., & Zhang, H. (2020) · Current Medical Science · doi:10.1007/s11596-020-2259-0 · Cited by 7
Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes
Straube, J., Lane, S., & Vu, T. (2021) · BioEssays · doi:10.1002/bies.202100125 · Cited by 7
EVI1 protein interaction dynamics: Targetable for therapeutic intervention?
Paredes, R., Doleschall, N. J., Connors, K., Geary, B., & Meyer, S. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.12.398 · Cited by 7
Biomedical marker molecules for cancer – current status and perspectives
Stoß, O., & Henkel, T. O. (2004) · Drug Discovery Today TARGETS · doi:10.1016/s1741-8372(04)02459-4 · Cited by 7
Molecular Signature Analysis: the Potential of gene-expression Analysis in Cardiomyopathy
Kittleson, M. M., & Hare, J. M. (2005) · Future Cardiology · doi:10.2217/14796678.1.6.793 · Cited by 7
“Similar results have been obtained for acute myeloid leukemia [47,48], prostate cancer [49,50] and central nervous system tumors [51].”
ResultMolecular Diagnostics of Acute Myeloid Leukemia
Wertheim, G. B. W., Daber, R. D., & Bagg, A. (2012) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.08.002 · Cited by 7
Issues of Processing and Multiple Testing of SELDI-TOF MS Proteomic Data
Birkner, M. D., Hubbard, A., van der Laan, M. J., Skibola, C. F., Hegedus, C. M., & Smith, M. T. (2006) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1198 · Cited by 7
“As discussed in van der Laan et al. (2005), the recently developed, resampling based E-Bayes/Bootstrap TPPFP approach has proven to be less conservative and thus more powerful, as compared to other methods, such as the augmentation approach outlined in van der Laan et al.”
Advances in the molecular genetics of acute leukemia
Scandura, J. M. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0058-1 · Cited by 7
The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes
Lilljebjörn, H., Peña‐Martínez, P., Thorsson, H., Henningsson, R., Rissler, M., Landberg, N., Puente‐Moncada, N., von Palffy, S., Rissler, V., Staněk, P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66546-6 · Cited by 9
“However, the feature with the strongest correlation to unsupervised gene expression-based clusters has been the apparent maturation stage of the leukemic cells 9,19,21 .”
MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities
Boertjes, E. L., Grob, T., Hinai, A. S. A. A., Beverloo, B. H. B., Versluis, J., Kavelaars, F. G., Rijken, M., Compagne, K. G., Erpelinck-Verschueren, C. A. J., Sanders, M. A., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018408 · Cited by 9
Self-citationO’Connell, G. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-41443-4 · Cited by 9
A Current View on Pathogenesis, Diagnosis, and Treatment of Some Rare Acute Leukemia Variants
Baranova, O. Y., & Shirin, A. D. (2022) · Clinical oncohematology · doi:10.21320/2500-2139-2022-15-4-307-326 · Cited by 8
NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia
Matsukawa, T., Yin, M., Nigam, N., Negi, V., Li, L., Small, D., Zhu, Y. J., Walker, R. L., Meltzer, P. S., & Aplan, P. D. (2023) · Leukemia · doi:10.1038/s41375-023-01913-0 · Cited by 8
“GSEA comparison to previously described AML signatures revealed strong similarity to “Valk_AML_Cluster_5”, which primarily consisted of patients with a monocytic or myelomonocytic (M4 or M5) AML subtype [13], and a group of AML patients with MLL gene fusions [14] (Supplementary Fig.”
ResultImmunophenotype distinctions of CEBPA mutation subtypes in acute myeloid leukemia
Liu, Q., Qi, L., Yang, M., Zhang, X., Li, F., Wei, H., & Wang, J. (2023) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14124 · Cited by 7
Vázquez‐Blomquist, D., Ramòn, A. C., Rosales, M., Pérez, G. V., Rosales, A. M., Palenzuela, D., Perera, Y., & Perea, S. E. (2023) · BMC Genomics · doi:10.1186/s12864-023-09472-5 · Cited by 6
Archer, K. J., Fu, H. H., Mrózek, K., Nicolet, D., Mims, A. S., Uy, G. L., Stock, W., Byrd, J. C., Hiddemann, W., Metzeler, K. H., et al. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100719 · Cited by 6
“28 Different genesdiscriminated betweenthe identi fi ed subgroups, suggesting there is heterogeneity among functional pathways that lead to AML.”
Sanders, M. A., Kavelaars, F. G., Zeilemaker, A., Hinai, A. S. A. A., Abbas, S., Beverloo, H. B., van Lom, K., & Valk, P. J. M. (2014) · Haematologica · doi:10.3324/haematol.2014.110775 · Cited by 6
“A subsequent study of 8 patients revealed that the t(11;16)(q23;p13) occurred exclusively in patients with therapy-related t-AML or tMDS, i.”
BackgroundSelf-citationStructural and Expression Changes of Septins in Myeloid Neoplasia
Cerveira, N., Santos, J., & Teixeira, M. R. (2009) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v15.i1-2.40 · Cited by 7
“…that class 1 and class 2 lesions occur together more commonly than do two class 1 or two class 2 lesions (Dash and Gilliland, 2001; Care et al., 2003; Downing, 2003; Valk et al., 2004b; Cammenga et al., 2005; Cairoli et al., 2006; Schnittger et al., 2006; Renneville et al., 2008).”
BackgroundMethodde la Blétière, D. R., Blanchet, O., Cornillet‐Lefèbvre, P., Coutolleau, A., Baranger, L., Geneviève, F., Luquet, I., Hunault, M., Beucher, A., Schmidt, A., et al. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-6 · Cited by 6
“With samples containing a high leukemic blast load, microarray-based gene expression profiling (GEP) and class prediction analyses have demonstrated their ability to assign AML samples to one of these three well characterized favorable cytogenetic risk AML subtypes, with high accuracy and low error rates [10-18].”
BackgroundOng, E., Szedlak, A., Kang, Y., Smith, P. B., Smith, N. H., McBride, M., Finlay, D., Vuori, K., Mason, J. R., Ball, E. D., et al. (2015) · Journal of Computational Biology · doi:10.1089/cmb.2014.0297 · Cited by 6
Metadata
- Authors
- Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., & Delwel, R.
- Affiliations
- Erasmus MC (NL)
- Leiden University Medical Center (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-15
- Volume
- 350
- Issue
- 16
- Pages
- 1617-1628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110502951
- Cited by
- 1,370
- References
- 30
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 27 · 2023: 40 · 2022: 30 · 2021: 59 · 2020: 49 · 2019: 50 · 2018: 40 · 2017: 39 · 2016: 66 · 2015: 53 · 2014: 64 · 2013: 72 · 2012: 86
- FWCI
- 63.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Erasmus Medisch Centrum
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, gene expression profiling, prognostic stratification, molecular signatures, patient clustering, inv(16), CEBPA mutation, chromosomal abnormalities, normal karyotype, treatment outcomes
- MeSH terms
- Acute Disease, Adult, Algorithms, Chromosome Aberrations, Female, Humans, Karyotyping, Leukemia, Myeloid, Male, Middle Aged, Mutation, Prognosis, Software, Gene Expression, Multivariate Analysis, Cluster Analysis, Survival Analysis, Oligonucleotide Array Sequence Analysis, Cytogenetic Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.